Compare ADMA Biologics Inc (ADMA) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Chipotle Mexican Grill, Inc. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Chipotle Mexican Grill, Inc. trades at $33.31 (market cap $44.06B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 20.7× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | CMG | |
|---|---|---|
Market Cap | $2.13B | $44.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $56.41 |
52-Week Low | $7.60 | $28.17 |
Enterprise Value | $2.20B | $48.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Chipotle Mexican Grill (CMG) trades at $34.35, down 2.91% over 24 hours, with a bullish technical signal from moving averages and strong fundamentals including a 49.23% ROE and consistent earnings beats. Revenue grew to $11.93B in 2025, though net cash flow turned negative due to aggressive financing activities. Recent news highlights operational excellence and menu innovation as growth drivers amid competitive pressures.
Outlook remains positive with a $40.46 analyst consensus price target (70% buy ratings), but risks include cost inflation and softer comps. The stock offers upside from execution of expansion plans, yet investors face headwinds from consumer sentiment and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
